News

As per the terms of the deal, the Japanese pharma company and Adaptimmune will select up to three targets for their collaboration and will co-develop T-cell therapy candidates

The organizations will form co-owned, joint development companies (“JDCs”) that will integrate Atomwise’s AI technology and BioMotiv’s deep expertise in preclinical and clinical development to translate innovative academic

Together, Charles River and Takeda will launch multiple integrated programs across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience, and rare disease—with the ultimate goal of delivering preclinical candidates

Ovaprene is Daré’s investigational hormone-free monthly vaginal contraceptive, which is under clinical development to prevent pregnancy. Under the exclusive licence agreement, Bayer will commercialise Ovaprene after it is

Under the marketing authorisation application (MAA) submitted to the European Medicines Agency (EMA), the company has asked the regulator to review the potential use of fostemsavir in combination

The rolling submission allows completed sections of an NDA to be reviewed by the FDA on an ongoing basis. Specifically, Alnylam has submitted the non-clinical components to the

The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. NeuroBo will focus on advancing the

Based in Menlo Park of California, Dermira is involved in the development of novel therapies to treat patients with chronic skin conditions. As per terms of the deal,

These investigational agents have potential for use in HIV long-acting therapies for treatment and prevention, as well as cure strategies. HIV bNAbs are a class of immunotherapy agents